Project Grant R01HL178894

Grant Award Summary

Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $1,725,948 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) effective July 15, 2026, with completion targeted for June 30, 2028. The award funds real-world effectiveness and value research on glucagon-like peptide-1 receptor agonists (GLP-1RAs) for prevention of cardiovascular disease among individuals with cardiovascular-kidney-metabolic syndrome. The project will generate real-world evidence on the effectiveness, safety, and value of GLP-1RAs, addressing a critical evidence gap where randomized controlled trials are limited or lack generalizability to diverse U.S. populations—particularly for primary prevention use among individuals with overweight or obesity but without diabetes, estimated to represent approximately 97.5 million treatment-eligible U.S. adults.

The research will examine GLP-1RA treatment outcomes, including long-term adherence patterns, adverse effects of therapy discontinuation, and post-marketing safety surveillance and cost-effectiveness assessments. This real-world evidence study is designed to inform clinical practice and healthcare policy decisions regarding GLP-1RA utilization in the U.S. healthcare system, particularly where traditional large-scale randomized trials are infeasible due to prohibitive costs, duration, and complexity requirements.